"Eden's solution is to have a product which can use the mechanical properties of MWCNT which is far cheaper to produce and to do so in the most efficient method for which they have patents."
Have you any proof that the EDE process for producing MWCNT is far cheaper?
The EDE process is optimised for hydrogen production with CNT as a byproduct. From a chemistry perspective it suggests that the EDE process would be be (much) more expensive than one optimised for CNT production.
"Secondly, they have the rights to the IP for dispersing MWCNT in solution which makes a very convenient additive (I am guessing it doesn't work with SWCNT). "
There is apparently no IP associated with Edencrete except the trademark
"They have created a market for essentially the waste product of the hythane technology, and turned it into the primary product.'
As I said above IMO the process is optimised for hydrogen and is likely to be (much) more expensive than a process optimised for CNT..
"Even if someone came up with a competitive product, its unlikely they could source the MWCNT at a competitive price and in the quantities they would need. Eden simply has no real competition. It is revolutionary."
There is currently a massive surplus of CNT production globally. AFAIK only about 50 tonnes (1-2%of annual capacity) is currently sold. So it is probably very easy to source MWCNT at a competitive price. EDE would need to build roughly 500 reactors to match the current global capacity of 3000 tonnes pa.
IMO there is no real mass market for CNT concrete at this stage.
IMO Edencrete doesn't seem much different to any other CNT reinforced concrete when used at the same CNT levels.
- Forums
- ASX - By Stock
- EDE
- Time is running out for Edencrete
EDE
eden innovations ltd
Add to My Watchlist
0.00%
!
0.2¢

Time is running out for Edencrete, page-133
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.219M |
Open | High | Low | Value | Volume |
0.2¢ | 0.2¢ | 0.2¢ | $3.202K | 1.600M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
71 | 172403254 | 0.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.2¢ | 15741752 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
69 | 170903254 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.002 | 15686752 | 5 |
0.003 | 22477721 | 29 |
0.004 | 13209547 | 13 |
0.005 | 3525777 | 9 |
0.006 | 943493 | 3 |
Last trade - 10.41am 04/07/2025 (20 minute delay) ? |
Featured News
EDE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online